KISSH
Kisshealth Biotechnology Co., Ltd., automatic solution provider of in vitro pathological diagnosis and immunodiagnosis.
Kisshealth Biotechnology Co., Ltd., automatic solution provider of in vitro pathological diagnosis and immunodiagnosis.
Kissh is a diagnostics company dedicated to developing and manufacturing IVD tests at the Point-of-Care with innovative proprietary technology. Specializing in the markets of in vitro pathological diagnosis and immunodiagnosis, they have developed, manufactured, and successfully launched the in vitro immunodiagnosis platform for cancer as well as the POCT for infectious, genetic, and chronic diseases. Established in 2018 in the Pingshan District, Shenzhen, P.R. China, Kissh received a CNY10.00M Angel Round investment on 01 June 2019 from Reading Capital. Emphasizing their slogan, "Leading the Future of Diagnostic Innovation in Emerging Markets," Kissh is positioned for significant growth and impact in the Health Care and Manufacturing industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Angel Round | CNY10.00M | 1 | Reading Capital | 01 Jun 2019 |
No recent news or press coverage available for KISSH.
We care about your data, and we'd love to use cookies make your experience better.